2022
33-OR: ADA Presidents' Select Abstract: Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod 5 Automated Insulin Delivery (AID) System
DESALVO D, BODE B, FORLENZA G, LAFFEL L, BUCKINGHAM B, CRIEGO A, SCHOELWER M, MACLEISH S, SHERR J, HANSEN D, LY T. 33-OR: ADA Presidents' Select Abstract: Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod 5 Automated Insulin Delivery (AID) System. Diabetes 2022, 71 DOI: 10.2337/db22-33-or.Peer-Reviewed Original ResearchDiabetic ketoacidosisSevere hypoglycemiaMannKind CorporationGlycemic outcomesExtension studyEpisodes of diabetic ketoacidosisOccurrence of severe hypoglycemiaNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchChildren Aged 2Type 1 diabetesStandard therapySafety endpointsPivotal studiesPotential long-term benefitsKidney diseaseStudy groupGlucose targetsLong-term benefitsSpeakers bureauImprove glycemic outcomesAged 2MedtronicGlycemic benefits765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
SCHOELWER M, BODE B, CARLSON A, CRIEGO A, FORLENZA G, WEINSTOCK R, HANSEN D, BUCKINGHAM B, MEHTA S, LAFFEL L, SHERR J, LEVY C, HIRSCH I, MACLEISH S, DESALVO D, SHAH V, BHARGAVA A, JONES T, ALEPPO G, GURLIN R, LY T. 765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. Diabetes 2022, 71 DOI: 10.2337/db22-765-p.Peer-Reviewed Original ResearchDaily insulin doseMannKind CorporationInsulin doseGlycemic outcomesEvaluate glycemic outcomesHigher TIRNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchType 1 diabetesEli Lilly and CompanySpeakers bureauInsulin requirementsAid useKidney diseaseInsulin needsMannKindCohort of peopleMedtronicTherapy phaseAged 2Janssen PharmaceuticalsOlder ageDiabetesT1D100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results
VIGERSKY R, BODE B, BRAZG R, BUCKINGHAM B, CARLSON A, KAISERMAN K, KIPNES M, LILJENQUIST D, PHILIS-TSIMIKAS A, PIHOKER C, POP-BUSUI R, REED J, SHERR J, SHULMAN D, SLOVER R, THRASHER J, CHEN X, LIU M, CORDERO T, VELLA M, RHINEHART A, SHIN J. 100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results. Diabetes 2022, 71 DOI: 10.2337/db22-100-lb.Peer-Reviewed Original ResearchMannKind CorporationSpeakers bureauKidney diseaseNovo NordiskEli LillyAdvisory PanelNational InstituteHealth researchMonths of useEffectiveness endpointReata PharmaceuticalsGlycemic controlPivotal trialsSevere hypoglycemiaEffectiveness outcomesGlycemic metricsDiabetesBayer AGHealth groupsRoche DiagnosticsUnitedHealth GroupLexicon PharmaceuticalsMiniMedTarget rangeSanofi
2021
70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D)
SHERR J, BODE B, FORLENZA G, LAFFEL L, BROWN S, BUCKINGHAM B, CRIEGO A, DESALVO D, MACLEISH S, HANSEN D, LY T. 70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D). Diabetes 2021, 70 DOI: 10.2337/db21-70-or.Peer-Reviewed Original ResearchDiabetes careDiabetic ketoacidosisStandard therapySevere hypoglycemiaSpeakers bureauEli LillyYoung childrenPrimary safety outcomePrimary effectiveness outcomeSerious adverse eventsAdvisory PanelLexicon PharmaceuticalsDaily dose requirementsType 1 diabetesNovo NordiskBoehringer Ingelheim PharmaceuticalsMannKind CorporationPermissive hyperglycemiaBaseline characteristicsHybrid closed-loop systemT1D durationAdverse eventsGlucose targetsEfficacy analysisInsulin delivery systems
2020
67-OR: Benefit of Reduced Hypoglycemia with Continuous Glucose Monitoring (CGM) Is Sustained through 12 Months among Young Children with Type 1 Diabetes (T1D)
VAN NAME M, MILLER K, KANAPKA L, TAMBORLANE W, DIMEGLIO L. 67-OR: Benefit of Reduced Hypoglycemia with Continuous Glucose Monitoring (CGM) Is Sustained through 12 Months among Young Children with Type 1 Diabetes (T1D). Diabetes 2020, 69 DOI: 10.2337/db20-67-or.Peer-Reviewed Original ResearchContinuous glucose monitoringCGM groupBlood glucose monitoringBehavioral interventionsEfficacy of CGMGlucose monitoringFamily behavioral interventionsType 1 diabetesYoung childrenEisai Inc.MannKind CorporationReduced hypoglycemiaSanofi USLess hypoglycemiaMedian ageMedian timeHarry B. Helmsley Charitable TrustTrial completionCGM useHypoglycemiaDurable reductionInsulin pumpBGM groupSimilar reductionWeeks380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM)
LIPSKA K, DOYLE M, CENGIZ E, DROZDOWICZ B, GILL T, MURPHY T, INZUCCHI S. 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM). Diabetes 2020, 69 DOI: 10.2337/db20-380-p.Peer-Reviewed Original ResearchContinuous glucose monitoringNursing home residentsHome residentsNursing homesConsecutive blood glucose levelsFlash continuous glucose monitoringPatients 65 yearsChronic kidney diseaseFrequency of hypoglycemiaLexicon PharmaceuticalsType 2 diabetesBlood glucose levelsWilcoxon rank sum testRank sum testMannKind CorporationAdvisory PanelConnecticut nursing homesADL disabilityMedian ageKidney diseaseNovo Nordisk A/SCGM periodGlucose levelsHypoglycemiaLong-term residents1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia
SHERR J, BUCKINGHAM B, FORLENZA G, GALDERISI A, EKHLASPOUR L, WADWA R, ZGORSKI M, KINGMAN R, BERGET C, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-1296-p.Peer-Reviewed Original ResearchDiabetes careGlucose targetsEli LillySerious adverse eventsHigh-fat mealRisk of hypoglycemiaAdvisory PanelType 1 diabetesChildren Aged 2MannKind CorporationHybrid closed-loop systemT1D durationAdverse eventsT1D ExchangeFat mealGlucose managementMean glucosePivotal studiesAged 2Bolus challengeDaily exerciseInvestigational deviceDlPercent timeTarget glucose978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia
FORLENZA G, BUCKINGHAM B, SHERR J, WADWA R, GALDERISI A, EKHLASPOUR L, BERGET C, HSU L, ZGORSKI M, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-978-p.Peer-Reviewed Original ResearchDiabetes careMeal bolusEli LillyPercent timeRisk of hypoglycemiaAdvisory PanelType 1 diabetesHigh-fat dinnerMannKind CorporationHybrid closed-loop systemT1D durationGlucose targetsT1D ExchangeGlucose managementPivotal studiesDaily exerciseInvestigational deviceDlTarget glucoseCareLexicon PharmaceuticalsMedtronicBolusLower targetsAdults
2019
1141-P: Detailed Phenotype of Randomized Participants by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
ARODA V, KRAUSE-STEINRAUF H, BUSE J, GULANSKI B, FLOREZ H, AHMANN A, LOVELAND A, KUHN A, LONIER J, MATHER K, WEXLER D. 1141-P: Detailed Phenotype of Randomized Participants by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes 2019, 68 DOI: 10.2337/db19-1141-p.Peer-Reviewed Original ResearchNovo Nordisk A/SMannKind CorporationBaseline characteristicsKidney diseaseSpouse/partnerInclusion criteriaClinical phenotypeAge groupsGlycemia Reduction ApproachesComparative effectiveness studiesDistinct clinical phenotypesNational InstituteEli LillyAdvisory PanelEisai Inc.More CVDProminent hyperglycemiaSecond medicationAdvancing Translational SciencesDiabetic dyslipidemiaMore medicationsPrevalent comorbiditiesRandomized participantsAge-related differencesRandomized treatment1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation
SCHIAVON M, GALDERISI A, KRAEMER K, COBELLI C, MAN C, CENGIZ E. 1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation. Diabetes 2019, 68 DOI: 10.2337/db19-1054-p.Peer-Reviewed Original ResearchContinuous glucose monitoringInsulin sensitivityType 1 diabetesEuropean Medical Information FrameworkInsulin pump dataClosed-loop treatmentOral minimal modelMannKind CorporationSequential mealsInsulin therapyMeal studyPlasma glucoseGlycemic outcomesType 1Glucose monitoringSpeakers bureauMeal variationT1D.T1DInternational SocietyAdvisory PanelPump dataTreatmentSI indexDiabetes1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D
DANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.Peer-Reviewed Original ResearchOptimized insulin therapyInsulin therapySpouse/partnerSanofi USDiabetes careDohme Corp.Novo Nordisk A/SSanofi-AventisEli LillyMerck SharpAdvisory PanelPhase 3 studyLexicon PharmaceuticalsOptimal glycemic controlRisk of hypoglycemiaLevel 2 hypoglycemiaLower ratesAmgen Inc.Boehringer Ingelheim PharmaceuticalsDual SGLT1Important hypoglycemiaMannKind CorporationPatient yearsWeek 52Glycemic control1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange
LEVY C, FOSTER N, DUBOSE S, AGARWAL S, LYONS S, PETERS A, UWAIFO G, DIMEGLIO L, SHERR J, POLSKY S. 1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange. Diabetes 2019, 68 DOI: 10.2337/db19-1424-p.Peer-Reviewed Original ResearchPregnant womenMannKind CorporationSanofi USKidney diseaseDiabetes FoundationPump useT1D Exchange Clinic RegistryEli LillyLexicon PharmaceuticalsBarbara Davis CenterInsulin pump useCohort of womenType 1 diabetesReal-world populationNational InstituteAdvisory PanelHelmsley Charitable TrustHealth researchPregnancy outcomesGlycemic controlSevere hypoglycemiaClinic registrySelf-reported useT1D ExchangeNovo Nordisk A/S2418-PUB: Incident Diabetes Complications among Women with T1D Based on Parity
POLSKY S, FOSTER N, DUBOSE S, AGARWAL S, LYONS S, PETERS A, UWAIFO G, DIMEGLIO L, SHERR J, LEVY C. 2418-PUB: Incident Diabetes Complications among Women with T1D Based on Parity. Diabetes 2019, 68 DOI: 10.2337/db19-2418-pub.Peer-Reviewed Original ResearchStudy enrollmentMannKind CorporationSanofi USKidney diseaseDiabetes FoundationT1D Exchange Clinic RegistryCardiovascular disease risk factorsEli LillyRate of neuropathyDisease risk factorsDiabetes-related complicationsLexicon PharmaceuticalsBarbara Davis CenterBody mass indexType 1 diabetesNational InstituteAdvisory PanelHelmsley Charitable TrustHealth researchYear of enrollmentRace/ethnicityPreg groupPregnant cohortClinic registryMass index275-LB: Connectome Predictive Modeling May Identify Brain Connectivity Signatures to Help Predict Who Will Benefit from Low-Calorie Diet
GROSKREUTZ D, LAM W, LACADIE C, ELSHAFIE A, HWANG J, SEO D, SAVOYE M, SINHA R, CONSTABLE T, SHERWIN R, BELFORT-DEAGUIAR R. 275-LB: Connectome Predictive Modeling May Identify Brain Connectivity Signatures to Help Predict Who Will Benefit from Low-Calorie Diet. Diabetes 2019, 68 DOI: 10.2337/db19-275-lb.Peer-Reviewed Original ResearchLow-calorie dietCalorie dietWeight lossBrain connectivity matricesEffective weight loss strategyFunctional MRIConnectivity signaturesBrain connectivityWeight loss strategiesReduced calorie dietWeight loss successNon-food imagesMannKind CorporationOB subjectsT2DM subjectsBMI changeLoss strategiesBrain-behavior relationshipsBrain connectivity dataEuglycemiaHyperglycemiaFood picturesDietNational InstituteBOLD activity
2018
Glycemic Variability from CGM Correlates with Indices of Glucose Metabolism in Healthy Obesity but Not in Type 2 Diabetes
ELSHAFIE A, LAM W, PARIKH L, RANGEL E, SCHMIDT C, HWANG J, YECKEL C, SHERWIN R, BELFORT-DEAGUIAR R. Glycemic Variability from CGM Correlates with Indices of Glucose Metabolism in Healthy Obesity but Not in Type 2 Diabetes. Diabetes 2018, 67 DOI: 10.2337/db18-82-lb.Peer-Reviewed Original ResearchGlucose infusion rateInsulin secretion-sensitivity index-2Beta-cell functionContinuous overlapping net glycemic actionGlucose variabilityContinuous glucose monitorT2D subjectsObese subjectsInsulin levelsGV indicesGlucose metabolismCell functionInsulin sensitivity indexType 2 diabetesGlycemic Risk AssessmentCGM indicesHealthy obesityMannKind CorporationHealthy obeseOB subjectsGlycemic excursionsInsulin resistanceIncremental AUCGlycemic variabilityRegeneron PharmaceuticalsManagement of Hypertension and Hyperlipidemia in Youth with T2D
BEAULIEU L, CHENG P, KATZ M, LAFFEL L, TAMBORLANE W, VAN NAME M, BANSAL N, KOLLMAN C, GAL R. Management of Hypertension and Hyperlipidemia in Youth with T2D. Diabetes 2018, 67 DOI: 10.2337/db18-1342-p.Peer-Reviewed Original ResearchTreatment of hypertensionBoehringer Ingelheim PharmaceuticalsLifestyle changesMedtronic MiniMedBoehringer Ingelheim GmbHPatient-related barriersManagement of hypertensionUrban academic centerEli LillyAdditional cardiovascular diseaseSelf-reported practicesMannKind CorporationSanofi USCVD complicationsLifestyle modificationGlycemic controlPatient adherenceDiabetes careTreatment recommendationsCardiovascular diseaseHypertensionPatient's perspectiveDiabetes InstituteHyperlipidemiaPhysical activityExceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG Study
PINSKER J, LI Z, BUCKINGHAM B, FORLENZA G, CENGIZ E, CHURCH M, EKHLASPOUR L, PAUL WADWA R, WEINZIMER S, ANDRE C, MARCAL T, JOST E, CARRIA L, WOODALL W, DOKKEN B, SWANSON V, LUM J, KOLLMAN C, BECK R. Exceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG Study. Diabetes 2018, 67 DOI: 10.2337/db18-86-lb.Peer-Reviewed Original ResearchRisk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D)
MEHTA S, WU M, FOSTER N, POP-BUSUI R, KATZ M, CRANDALL J, BACHA F, NADEAU K, LIBMAN I, HIERS P, MIZOKAMI-STOUT K, DIMEGLIO L, SHERR J, PRATLEY R, AGARWAL S, SNELL-BERGEON J, CENGIZ E, POLSKY S, SHAH V. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D). Diabetes 2018, 67 DOI: 10.2337/db18-15-lb.Peer-Reviewed Original ResearchCVD risk factorsIncident cardiovascular diseaseRisk factorsCardiovascular diseaseDiabetic nephropathyT1D Exchange Clinic RegistryTraditional CVD risk factorsEli LillyPediatric Diabetes ConsortiumBlood pressure medicationsIschemic heart diseaseImportant risk factorType 1 diabetesNon-fatal eventsNational InstituteYears of ageBoehringer Ingelheim PharmaceuticalsAdvisory PanelEisai Inc.MannKind CorporationDiabetes durationComposite outcomeHeart failureClinic registryContemporary cohortIncreased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D)
CLEMENTS M, WU M, FOSTER N, LAFFEL L, SHAH V, VENDRAME F, KINGMAN R, ALONSO G, CARLSON A, DESALVO D, BUCKINGHAM B, SHERR J, BENJAMIN R, EYTH E, DUBOSE S. Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D). Diabetes 2018, 67 DOI: 10.2337/db18-26-lb.Peer-Reviewed Original ResearchRisk of microalbuminuriaSD HbA1cDiabetes careT1D Exchange Clinic RegistryShorter diabetes durationSpeakers bureauType 1 diabetesAge of diagnosisEli LillyBoehringer Ingelheim PharmaceuticalsAdvisory PanelMannKind CorporationMicroalbuminuria developmentSanofi USDiabetes durationMean HbA1cT1D durationRenal diseaseClinic registryRegistry enrollmentClinic visit recordsT1D populationMedian numberMicroalbuminuriaDiabetes InstituteShort-Term Weight Loss Undermines Brain Regulation of Food Consumption
LAM W, SEO D, LACADIE C, SCHMIDT C, ROSENBERG S, HOANG H, HWANG J, CONSTABLE T, SAVOYE M, SINHA R, SHERWIN R, BELFORT-DEAGUIAR R. Short-Term Weight Loss Undermines Brain Regulation of Food Consumption. Diabetes 2018, 67 DOI: 10.2337/db18-1802-p.Peer-Reviewed Original ResearchWeight lossTest mealBrain regulationAd libitum test mealShort-term weight lossFunctional MRIBrain activityWeight loss maintenanceTotal calorie intakePost-prandial hyperglycemiaFood consumptionHigh-calorie food picturesMannKind CorporationSuppress appetiteCalorie dietOB subjectsLoss maintenanceObese individualsHyperglycemic clampRegeneron PharmaceuticalsAppetite controlFood intakeCalorie intakeGlaxoSmithKline plcHyperglycemia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply